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Summary
PRINCIPLES: Apolipoprotein E (ApoE), an important gly-
coprotein in the transport, uptake and redistribution of cho-
lesterol, is necessary in nerve tissue repair. The APOE
gene (APOE) is involved in neurodegenerative diseases,
the best-known association being that between the APOE
ε4 allele and Alzheimer’s disease. Multiple sclerosis (MS)
is a chronic inflammatory neurological disease. The aim of
this study was to assess (multicentre assessment) the pos-
sible influence of the APOE gene on the susceptibility of
primary progressive MS (PPMS) in Hungary.
METHODS: Polymerase chain reaction and restriction
fragment length polymorphism were carried out on DNA
isolated from 135 volunteers.
RESULTS: The number of PPMS patients without the
ε2 allele was found to be remarkably high, whilst the ε2 al-
lele was overrepresented in the RRMS group. A markedly
high frequency of the ε4 allele was found in the PPMS
group and a very low frequency in the HC group. With
regards to the clinical parameters, significant differences
were observed between the RRMS and PPMS groups. Dif-
ferences were also detected regarding the EDSS and MSSS
scores when the patients were grouped by the presence or
absence of the ε2 allele. All of the observed differences in
the clinical parameters disappeared when the patients were
further stratified by the type of MS.
CONCLUSIONS: Our findings suggest that the presen-
ce of the ε2 and ε4 alleles may play a role in the develop-
ment of the disease. However, if any type of the disease has
already developed the alleles show no association with the
clinical parameters.
Key words: Apolipoprotein E gene (APOE); Genetics;
Multiple sclerosis (MS); Primary progressive (PP); Single
nucleotide polymorphism (SNP)
Introduction
Apolipoprotein E (ApoE) plays important roles in the
transport, uptake and redistribution of cholesterol, which is
necessary in the repair of nerve tissue. While it primarily
functions as a lipid transporter, it is also linked to ather-
osclerosis, cognitive function, immunoregulation, neurite
outgrowth, brain trauma and infectious diseases [1]. The
APOE gene (APOE) is additionally involved in neuro-
degenerative diseases; the best-known association is that
between the APOE ε4 allele and Alzheimer’s disease [3].
Multiple sclerosis (MS) is a chronic inflammatory neurolo-
gical disease caused by numerous factors. The heterogen-
eous nature of the disease leads to different clinical mani-
festations. In the majority of MS patients the disease begins
with a relapsing course (relapsing-remitting form; RRMS),
characterised by relapses and remissions, followed by a
progressive phase (secondary progressive MS; SPMS). The
pathological hallmark is the primary inflammation and the
secondary neurodegeneration. In a smaller subset of pa-
tients, the relapsing phase is absent and the disease pro-
gresses from the very beginning (primary progressive
form; PPMS). In this subtype, the neurodegeneration is the
driving force [4].
Two single base polymorphisms within exon 4 of the
APOE, at codons 112 and 158, result in three common al-
leles (ε2, ε3 and ε4); the corresponding protein variants
ApoE2, E3 and E4 are distinguishable by having different
combinations of the amino acids arginine and cysteine at
these positions [1, 2]. ApoE is produced in various organs
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and tissues, predominantly in the liver and by the astrocytes
in the brain. ApoE3 seems to be the normal form, while
ApoE2 and ApoE4 can each be dysfunctional. The protein
is a glycoprotein that contains 299 amino acids, with a mo-
lecular weight of 34 kDa.
The literature reports on the role of APOE in MS are
controversial (table 1). In addition, no Hungarian data is
available regarding the APOE status of MS patients. Con-
sequently, our aim was to evaluate the role of the APOE
gene in Hungarian PPMS patients. The hypothesis of
present study was that the ε4 allele is associated with pro-
gression, while the ε2 allele is rather protective.
Patients and methods
Patients
All patients gave their informed consent for participation
in accordance with the Declaration of Helsinki (1964) and
the study was approved by the local ethics committee (pro-
tocol no. 16/2006). Over a period of one year (between
2006 June and 2007 June), participation in the study was
offered to PPMS patients who were consecutively referred
to one of the 5 involved Hungarian MS Centres at the reg-
ular check-up every 5 months. The APOE genotype was
determined from the blood of 45 PPMS patients, 45 age-
and sex-matched RRMS patients and 45 healthy controls
(HC). The two latter groups served as control groups for
the PPMS group. A total of 13 of the 45 PPMS patients
were followed up at the MS Outpatient Unit of the Depart-
ment of Neurology at the University of Szeged, 12 patients
at the Department of Neurology at the University of Pécs,
7 patients at the Department of Neurology at Ferenc Jahn
Hospital in Budapest, 7 patients at the Department of Neur-
ology at the County Hospital in Kecskemét, and 6 patients
were followed up at the Department of Neurology at the
University of Debrecen. The RRMS patients and HC sub-
jects were selected according to age and sex from Szeged.
Clinical data (the Expanded Disability Status Scale (EDSS)
score [5], date of birth, year of diagnosis and onset of the
disease) were collected by using the up-to-date MS register.
The Multiple Sclerosis Severity Score (MSSS) [6] and the
progression index (PI; the ratio between the EDSS score
and the disease duration in years) were also determined.
The EDSS scores the disability by evaluating the degree of
neurological impairment and it has steps from 0 (normal)
to 10 (death due to MS). The MSSS gives a hint as to the
severity of the disease, expressed numerically via the ex-
tent of disability and the disease duration. The RRMS pa-
tients met the McDonald diagnostic criteria [7]. The PPMS
patients had undergone at least one year of disease progres-
sion and had had a positive brain or spinal cord MRI or
positive cerebrospinal fluid [8]. The patients were relapse-
free and were not taking steroids for at least 1 month before
the assessment. In Hungary, a central database of healthy
controls for genetic research is not available. We therefore
offered study participation to age and sex-matched attend-
ants and relatives of MS patients and to healthy staff at the
clinic. If the health inclusion criteria were satisfied (no cur-
rent acute or chronic physical or mental illness), the parti-
cipant signed an informed consent form.
Methods
DNA analysis and genotyping
Genomic DNA was extracted from 1 ml EDTA-treated
peripheral blood. For extraction, the GenisolTM Maxi-Prep
Kit (ABgene House, Epsom, UK) was used.
Table 1: Summary of studies investigating the association between APOE and MS.
First author Country Number of MS subtype
patients
Findings
Cocco Sardinia 773 RR; 98 PP Gender-specific association between ε4 and PP
Chapman Israel 47 RR ε4 allele increases rate of disease progression
Chapman Israel 172 RR; 31 SP; 2 PP ε4 allele associated with faster progression of disability
Fazekas Austria 76 RR; 5 SP; 2 PP More extensive tissue destruction or less efficient repair in carriers of the ε4 allele
Fazekas Austria 253 RR; 97 SP; 24 PP An association of ε4 allele with a more severe course
Høgh Denmark 104 RR; 29 PP; 105 SP ε4/ε4 genotype risk for developing MS and faster disease progression
Schmidt USA 379 RR; 30 PP; 182 SP; 19 PR Association between ε4 and a more severe form and between ε2 and mild disease
Pinholt Denmark 249 RR; 94 SP; 42 PP ε4 allele associated with faster progression
Evangelou UK 52 RR; 32 SP; 11 PP ε4 allele associated with more rapid progression
Al-Shammri Kuwait 33 RR; 5 RP; 1benign MS No association (only trend toward) between disease severity and ε4 allele
Ferri Italy 161 RR No association with occurrence of MS
Niino Japan 95 RR; 40 SP No association with disease progression
Weatherby UK 162 RR; 188 SP; 20 PP No association with occurrence or clinical course
Zwemmer The Netherlands 159 RR; 159 SP; 90 PP Disease severity not associated to carriership of ε4 or ε2
Masterman Sweden 124 benign; 140 severe No significant differences between the benign and severe MS
Santos Portugal 34 PP; 184 other form ε4 not associated to disease progression only in a subset of patients with <10 yrs disease
duration
Portaccio Italy 75 RR; 40 BMS; 49 SP; 9 PP No association with disease course and severity
Bonetti Finland 459 MS trio families No association
Savettieri Italy 319 RR; 90 SP; 19 PP Association between ε2 allele and longer disease duration
Ballerini Italy 32 CP; 34 stable MS ε2 allele has protective role against the onset of the progression form
Kantarci Turkey 221 MS Gender-specific association between APOE ε2 and lesser disease severity
Abbreviations: APOE= apolipoprotein E gene; BMS = benign multiple sclerosis; CP = chronic progressive; MS = multiple sclerosis; PP = primary progressive; RR =
relapsing remitting; SP = secondary progressive;
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To determine the genotype, we applied a polymerase
chain reaction (PCR) on a 2720 Thermal Cycler (produced
by PE Applied Biosystems) by using the primers
5’-TCCAAGGAGCTGCAGGCG-3’ and
5’-CCGGCCTGGTACACTGCC-3’. The oligonucleotides
were from the Biological Research Centre, Hungarian
Academy of Sciences, Szeged.
The primers created a restriction site for the Hin6I en-
zyme (Fermentas) (5’-G^CGC-3’). The digestion products
were resolved on polyacrylamide gel and detected under
ultraviolet light after staining with ethidium bromide. The
ε2 allele gave visible fragments of 91 and 83 bp, the ε3 al-
lele gave fragments of 91 and 48 bp, and the ε4 allele gave
fragments of 72 and 48 bp.
Statistical analysis
T-test and variance analysis were used to detect the differ-
ences among the three groups with regards to the demo-
graphic and clinical parameters. We grouped the subjects
by the presence or absence of the ε2, ε3 or ε4 alleles be-
cause the sample size did not allow groups to be made for
all possible genotypes. The Pearson chi squared test was
performed to study the distribution of the alleles by the
investigated groups. The p values were calculated on the
basis of adjusted residual values. These values revealed the
extent of the discrepancy between the observed and the ex-
pected frequencies in the cell (residual) in the examined
group and standardised it. The combined effect of the MS
course and the alleles on the clinical parameters was ana-
lysed with a two-way analysis of variance. Due to the mul-
tiple comparisons, the level of significance was chosen to
be p <0.005. For all statistical analyses, the SPSS 15.0 stat-
istical package was used.
Results
The population analysed was in Hardy-Weinberg equilibri-
um, because the value of the goodness-of-fit test was p =
0.082 (Chi2 = 9.78, d.f = 5). The demographic data on the
three groups are displayed in table 2. As the groups were
age- and sex-matched, there were no differences by gender
or mean age (p = 0.998). The age at onset in the PPMS pa-
tients was higher and the disease duration was shorter than
in the RRMS patients but not significantly (p = 0.404 and p
= 0.316, respectively). In the PPMS form, the EDSS score,
the PI and the MSSS values were higher compared with
those for the RRMS group (p <0.001).
Due to the low number of subjects with absence of the
ε3 allele (5 RRMS and 1PPMS patients) grouping patients
by this allele was not possible (table 3). Neither є2/є2 nor
є4/є4 homozygote genotype was detected.
Table 4a and 4b show the occurrence of ε2 and ε4 al-
leles in the investigated groups. The number of the PPMS
patients without the ε2 allele was found to be remarkably
high (p <0.001), whilst the ε2 allele was overrepresented
in the RRMS group (p <0.003) (table 4a). In addition, the
pairwise comparisons indicated that the difference between
the RRMS and HC groups was also significant (p <0.001).
The presence of the ε4 allele was typical in the PPMS
and the RRMS groups (table 4b). A markedly high fre-
quency of this allele was found in the PPMS group (p
<0.001) and a very low frequency in the HC group (p
<0.001). The pairwise comparisons revealed that the fre-
quency of the ε4 allele was higher also in the RRMS group
than that in the HC group (p <0.05) and was twice as fre-
quent as in the PPMS group (p <0.005).
With regards to the clinical parameters (EDSS, PI and
MSSS), significant differences were observed between the
RRMS and PPMS groups (p <0.001 for all parameters;
table 2). Differences were also detected regarding the
EDSS and MSSS scores when the patients were grouped
by the presence or absence of the ε2 allele (p <0.004 and
p <0.001, respectively; table 5). As for the є4 allele, there
were no differences found in any of the clinical parameters
on the p = 0.005 decision level but on the p = 0.05 level the
MSSS value differed significantly (p = 0.045). All of the
observed differences in the clinical parameters disappeared
when the patients were further stratified by the type of MS.
Two-way analysis of the combined effect of the two
variables (presence or absence of the alleles and type of
MS) revealed that the difference in the clinical parameters
could only be attributed to the type of MS (table 6). Inter-
action between these variables could not be detected.
Discussion
The literature reports on the role of APOE in MS are con-
troversial, with claims that the presence [9–18] or absence
[19–28] of the APOE є4 allele is connected with the sus-
ceptibility to the disease or its severity. The role of the
APOE gene in MS has been extensively studied in recent
years, but the debate remains open (table 1). Studies on
the APOE status in the Hungarian MS population have not
been published so far, though the role of chromosome 19
was raised by Rajda et al. [29].
In the literature, the information relating to the genetic
background of PPMS patients is incomplete because of the
low number of such patients [10, 12–15, 17, 18, 24, 25].
Only two studies on APOE analysis (from Sardinia and
the Netherlands) involved a larger PPMS group than that
in the present study (table 1) [11, 26]. The prevalence of
MS in the Netherlands is 76 per 100,000 inhabitants [30],
Table 2: Demographic and clinical data of the three groups.
Group Patients number
Male/Female
Age
(years)
Age at onset
(years)
Disease duration
(years)
EDSS PI MSSS
PPMS 23/22 49.1 ± 10.5 38.0 ± 9.4 11.1 ± 8.9 5.7 ±1.8 0.96 ± 1.13 7.2 ± 2.0
RRMS 23/22 49.2 ± 9.8 36.3 ± 9.5 12.9 ±8.0 2.8 ± 1.9 0.32 ± 0.35 3.2 ± 2.5
HC 23/22 49.0 ± 10.6 – – – – –
p – 0.998 0.404 0.316 <0.001 <0.001 <0.001
Values are given as mean ± SD
Abbreviations: EDSS = Expanded Disability Status Scale; HC = healthy control; MSSS = Multiple Sclerosis Severity Score; PI = progression index; PPMS = primary
progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis
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while in Sardinia it is approximately 2.3-fold higher than
in Hungary [31, 32]. Accordingly, our group (approxim-
ately 7% of the Hungarian PPMS population) comprises
of a comparatively large sample, considering that the Hun-
garian prevalence is 62 per 100,000, the population of Hun-
gary is 10 million and 11% of Hungarian MS patients have
the PPMS form [31]. The study from Sardinia revealed that
the ε4 allele increases the risk of PPMS, but only in women
[11] whereas the study from the Netherlands did not con-
firm any association.
Table 3: Distribution of all APOE genotypes by the investigated groups.
MS patientsAPOE gene
PPMS (n = 45) RRMS (n = 45) HC (n = 45)
Total
Genotype
ε2/ε2 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
ε2/ε3 3 (6.7%) 17 (37.8%) 17 (37.8%) 37 (27.4)
ε2/ε4 1 (2.2%) 5 (11.1%) 0 (0.0%) 6 (4.4%)
ε3/ε3 18 (40.0%) 17 (37.8%) 24 (53.3%) 59 (43.7%)
ε3/ε4 23 (51.1%) 6 (13.3%) 4 (8.9%) 33 (24.4%)
ε4/ε4 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total 45 (100.0%) 45 (100.0%) 45 (100.0%) 135 (100.0%)
Abbreviations: APOE = apolipoprotein E gene; HC = healthy control; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis
Table 4a: The occurrence of the ε2 allele in the investigated groups.
HC PPMS RRMS Total
Count 28 41 23 92
% within group 62.2 91.1 51.1 68.1
non ε2
Adjusted residual (p) –1.0 (0.317) 4.0 (<0.001) –3.0 (0.003)
Count 17 4 22 43
% within group 37.8 8.9 48.9 31.9
ε2
Adjusted residual (p) 1.0 (0.317) –4.0 (<0.001) 3.0 (0.003)
Count 45 45 45 135Total
% within group 100.0 100.0 100.0 100.0
Pearson Chi-Square p <0.001
Table 4b: The occurrence of the ε4 allele in the investigated groups.
HC PPMS RRMS Total
Count 41 21 34 96
% within group 91.1 46.7 75.6 71.1
non ε4
Adjusted residual (p) 3.6 (<0.001) –4.4 (<0.001) 0.8 (0.424)
Count 4 24 11 39
% within group 8.9 53.3 24.4 28.9
ε4
Adjusted residual (p) –3.6 (<0.001) 4.4 (<0.001) –0.8 (0.424)
Count 45 45 45 135
% within group 100.0 100.0 100.0 100.0
Total
Pearson Chi-Square p <0.001
Abbreviations: HC = healthy control; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis
Table 5: Mean values of the measured clinical parameters of MS groups dependant on having or not having the ε2 or ε4 alleles.
PPMS RRMS PPMS and RRMS
N = 41 N = 4 N = 45 N = 23 N = 22 N = 45 N = 64 N = 26 N = 90
non ε2 ε2 Total
p
non ε2 ε2 Total
p
non ε2 ε2 Total
p
Disease duration
(year)
11.2 ± 8.9 10.3 ± 10.2 11.1 ± 8.9 0.872 12.7 ± 6.9 13.1 ± 9.2 12.9 ± 8.0 0.842 11.7 ± 8.2 12.7±9.2 12.0 ± 8.5 0.618
EDSS 5.6 ± 1.8 6.3 ± 2.1 5.7 ± 1.8 0.586 3.0 ± 2.1 2.6 ± 1.7 2.8 ± 1.9 0.429 4.7 ± 2.2 3.2±2.2 4.2 ± 2.3 0.004
PI 1.0 ± 1.2 0.6 ± 0.6 1.0 ± 1.1 0.475 0.3 ± 0.3 0.4 ± 0.4 0.3 ± 0.4 0.456 0.7 ± 1.0 0.4±0.5 0.6 ± 0.9 0.093
MSSS 7.2 ± 2.1 7.0 ± 0.8 7.2 ± 2.0 0.858 3.5 ± 2.6 3.0 ± 2.4 3.2 ± 2.5 0.534 5.9 ± 2.9 3.6±2.6 5.2 ± 3.0 0.001
PPMS RRMS PPMS and RRMS
N = 21 N = 24 N = 45 N = 34 N = 11 N = 45 N = 55 N = 35 N = 90
non ε4 ε4 Total
p
non ε4 ε4 Total
p
non ε4 ε4 Total
P
Disease duration
(year)
10.7 ± 8.4 11.5 ± 9.5 11.1 ± 8.9 0.768 14.2 ± 8.0 8.8 ± 6.9 12.9 ± 8.0 0.052 12.9 ± 8.3 10.6 ± 8.7 12.0 ± 8.5 0.226
EDSS 5.6 ± 1.9 5.7 ± 1.7 5.7 ± 1.8 0.934 3.0 ± 1.9 2.1 ± 1.8 2.8 ± 1.9 0.169 4.0 ± 2.3 4.6 ± 2.4 4.2 ± 2.3 0.287
PI 0.9 ± 0.9 1.0 ± 1.3 1.0 ± 1.1 0.819 0.3 ± 0.4 0.3 ± 0.3 0.3 ± 0.4 0.851 0.6 ± 0.7 0.8 ± 1.2 0.6 ± 0.9 0.242
MSSS 7.0 ± 2.2 7.4 ± 1.8 7.2 ± 2.0 0.530 3.3 ± 2.5 3.0 ± 2.7 3.2 ± 2.5 0.759 4.7 ± 3.0 6.0 ± 2.9 5.2 ± 3.0 0.045
Values are given as mean ± SD
Abbreviations: EDSS = Expanded Disability Status Scale; MSSS = Multiple Sclerosis Severity Score; PI = progression index; PPMS = primary progressive multiple
sclerosis; RRMS= relapsing-remitting multiple sclerosis
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A recent meta-analysis by Burwick et al. of the results
from a pooled analysis (353 PPMS cases) did not provide
any evidence of an association between the ε2 or ε4 carrier
status in PPMS [20]. The pooled analysis was performed
on the results of 11 published (from 10 different countries)
and one unpublished article, which is an average of 32 ±
26 PPMS subjects per article. However, this meta-analysis
did not include the results from Sardinia with 98 PPMS pa-
tients [11] or from Denmark with 42 PPMS patients [16].
Cocco et al. detected a gender-specific association between
the ε4 allele and the PPMS course whilst Pinholt et al.
found that the ε4 allele is associated with faster progression
(table 1). A study from a country geographically adjacent
to Hungary (Austria) detected an association between the
ε4 allele and rapid progression (24 PPMS subjects) [14].
The present study did not consider the genotype-phen-
otype relationship, however, in the series in the study by
Masterman et al. the APOE ε3/ε4 genotype was more com-
mon in severe MS than in benign MS [21]. Fazekas et al.
found that patients carrying the ε3/ε4 genotype exhibited
a significantly higher black hole ratio, demonstrating the
disabling effect of the є4 allele [13]. The black hole ratio
((T1-LL/T2-LL)*100), calculated by the total lesion load
on proton density weighted (T2-LL) and T1 weighted scans
(T1-LL), indicates the proportion of more severe tissue de-
struction among MS lesions. A study from Denmark indic-
ated that the є4/є4 homozygote genotype is a risk factor for
MS and determines the clinical progression [15].
Similarly as in other studies, we could not identify pa-
tients homozygous for the є4 allele [10, 11, 22, 34], most
probably because of the low number in the overall ex-
amined population. In contrast, 2.1–7.7% of the patients
were genotyped as є4/є4 in studies from Denmark [15, 16],
Sweden [21] and Kuwait [19].
The frequencies of the APOE alleles vary worldwide.
The predominant allele for most populations is the ε3 allele
(70–80%), which is often considered to be the ancestral al-
lele. We found this to be the most frequent allele in our
population (68.9% in the PPMS group, 63.3% in the RRMS
group and 76.7% in the HC group). While the proportion
of ε4 carriers increases steadily from 10–15% in southern
Europe to 40-50% in the north, the proportion of ε2 al-
lele carriers is slightly higher in central Europe than in the
south or the north [1]. The distributions of the є4 allele in
this study exhibited a wide range, from 4.4% to 26.7%, and
its frequency was outstandingly high in the PPMS group.
The є2 allele frequency was underrepresented in the PPMS
group (only 4.4%).
Concerning the relationship between the age at onset
and the APOE polymorphisms, a previous study concluded
that the є4 allele is associated with an earlier age of onset
in MS patients [10]. We did not observe a significant asso-
ciation between either the є4 or the є2 allele and the disease
duration.
Fewer studies have investigated the association of the
ε2 allele in MS. Some authors reported evidence of a pro-
tective effect of the ε2 allele [18, 33], but the meta-analysis
by Burwick et al. disputed this [20]. Our results provide
support for an association between carrying the є2 allele
and more favourable disease parameters. Furthermore, this
is in line with the findings of Savettieri et al. [24], Kantarci
et al. [35] and a study which demonstrated that patients
with the є3/є2 genotype had a significantly reduced and
delayed risk of chronic progressive MS [33]. The presence
of the є2 allele may possibly exert a protective effect
against progression.
The strength of the present study is that it was based
on a comparatively large number of a subpopulation with
a rare disease and examined a wide range of clinical para-
meters.
The limitations of this study are the low number of sub-
jects in the control groups; consequently increases in the
number of RRMS patients and healthy controls are clearly
needed. In addition, further SNP assessments (HLA) re-
lated to disease progression or association, and longitudinal
follow-ups completed with magnetic resonance findings
are suggested for a reliable result.
The present study is the first that has examined the pos-
sible association involving the APOE status in the popula-
tion of Hungarian PPMS patients. Based on the observed
differential occurrence of the ε2 allele in the PPMS and
the RRMS groups, we suspect that the presence of this al-
lele makes the patients susceptible to the RRMS course.
The observed distribution of the ε4 allele across the groups
indicated that this allele is linked with both forms of the
disease but with a higher propensity to the PPMS course.
Our findings suggest that the presence of the ε2 and ε4 al-
leles may play a role in the development of the disease.
However, if any type of the disease has already developed
the alleles show no association with the clinical paramet-
ers.
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Table 6: Results of the two-way analysis of variance.
p
Dependent variable: EDSS –
Type of MS <0.001
ε2 0.866
Grouping variables
Type of MS* ε2 0.327
Dependent variable: MSSS –
Type of MS <0.001
ε2 0.631
Grouping variables
Type of MS* ε2 0.838
Abbreviations: EDSS = Expanded Disability Status Scale; MSSS = Multiple Sclerosis Severity Score; MS = multiple sclerosis
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